Data sourced from BSE & NSE · Compiled by IPO Ji · IPO subscription data last updated
Total 75.06x·QIB 181.20x·NII 77.56x·Retail 13.65x
Based on retail subscription by applications (11.70×), approximately 1 in 12 retail applications may receive an allotment. Final allotment is decided by the registrar’s computerised lottery.
Symbiotec Pharmalab Limited Mainboard IPO was subscribed 75.06x in total when bidding closed on Aug 27, 2026, with 181.2x in the QIB category, 77.56x in NII, 13.65x in retail across BSE and NSE. This represents a strong oversubscription, reflecting heavy investor demand; a high subscription figure does not guarantee listing gains, and allotment follows the applicable category and exchange rules. The issue ran from Aug 24, 2026 to Aug 27, 2026 at a price band of ₹938–₹988 per share. Allotment was finalised on Aug 28, 2026.
| Category | Offer | Applied | Times |
|---|---|---|---|
| QIBs | 3550608 | 643359195 | 181.2 |
| NIIs | 2662955 | 206535120 | 77.56 |
| BNIIs (>10L) | 1775304 | 155046495 | 87.34 |
| SNIIs (<10L) | 887652 | 51488625 | 58.01 |
| Retail | 6213562 | 84810330 | 13.65 |
| Employee | 33408 | 545055 | 16.32 |
| Total | 12460533 | 935249700 | 75.06 |
| Total Applications52,59,328 approx. |
|||
| Category | Reserve | Applied | Times |
|---|---|---|---|
| BNIIs (>10L) | 8,454 | 1,50,254 | 17.77 |
| SNIIs (<10L) | 4,277 | 2,37,511 | 55.53 |
| Retail | 4,14,237 | 48,46,777 | 11.7 |
| Employee | - | 23,446 | - |
| Total Applications52,59,328 approx. |
|||
| Category | Offered | Demand | Times |
|---|---|---|---|
| QIBs | 350.8 | 63563.89 | 181.2 |
| FIIs | - | 12443.59 | - |
| DIIs | - | 36325.71 | - |
| Mutual Funds | - | 3457.09 | - |
| Others | - | 11337.50 | - |
| NIIs | 263.1 | 20405.67 | 77.56 |
| BNIIs (>10L) | 175.4 | 15318.59 | 87.34 |
| SNIIs (<10L) | 87.7 | 5087.08 | 58.01 |
| Retail | 613.9 | 8379.26 | 13.65 |
| Employee | 3.3 | 53.85 | 16.32 |
| TOTAL | 1231.1 | 92402.67 | 75.06 |
| As on | QIB |
NII
bHNI
sHNI
|
Retail | Total |
|---|---|---|---|---|
|
Day 1
24 Aug 2026
5:00 PM
|
0.37x |
1.10x
0.82x
1.66x
|
1.00x | 0.85x |
|
Day 2
25 Aug 2026
5:00 PM
|
0.57x |
3.16x
2.59x
4.30x
|
2.21x | 1.95x |
|
Day 3
26 Aug 2026
5:00 PM
|
0.62x |
12.84x
11.90x
14.72x
|
5.33x | 5.60x |
|
Day 4
27 Aug 2026
5:00 PM
|
181.20x |
77.56x
87.34x
58.01x
|
13.65x | 75.06x |
|
Day 5
28 Aug 2026
5:00 PM
|
181.20x |
77.56x
87.34x
58.01x
|
13.65x | 75.06x |
Anticipated subscription based on the number of applications received (an alternative to the shares-based figures above), sourced from BSE & NSE.
| Category | Times (by applications) |
|---|---|
| bHNI | 17.77x |
| sHNI | 55.53x |
| Retail | 11.70x |
Because Symbiotec Pharmalab closed oversubscribed, applicants were not guaranteed full allotment. In oversubscribed issues, shares are allotted according to the applicable category and exchange rules, so applicants are not guaranteed full allotment once an issue is oversubscribed. The number of times each category is subscribed is one indicator of demand, alongside the company's fundamentals and the broader market.
A high subscription figure reflects strong demand but does not guarantee a premium listing, and a low figure does not guarantee a discount. This page is for information only and is not investment advice. Investors should read the company's prospectus and consult a SEBI-registered adviser before making any decision.
IPO subscription status shows how many times an issue has been applied for, compared with the shares on offer, broken down by Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII), and the Retail or SME Individual Investor category. A figure of "2x" means investors applied for twice the shares available. See how IPO subscription works and track all live IPOs →
Data Source: The above information / data is sourced from National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) websites and is subject to change in real time. For latest information / data, please refer to the respective websites.
Purpose: The information / data provided herein is for informational purposes only and is provided by ipoji.com on "AS IS" and "AS AVAILABLE" basis and without warranty, express or implied.
Accuracy: ipoji.com does not warrant the accuracy, adequacy or completeness of the information you obtain through the above websites.
Liability: ipoji.com shall not be liable in any way for any discrepancies, errors, omissions, losses or damage. ipoji.com, including its affiliates and its directors, staff and employees, shall not be liable for any loss, damage of any kind, including but not limited to direct, indirect, punitive, exemplary, consequential damages and lost profits arising in any way out of the use of information / data obtained through the said websites.
User Responsibility: The recipient alone is fully responsible / liable for any decision made based on this information / data. All recipients, before relying on the said information, should do their own research and seek appropriate professional advice.